Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467021 · ClinicalTrials.gov registry record · NA
Cancer and Blood Pressure Management, CARISMA Study
A NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT04467021 is a NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 61 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04467021, a NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Blood Pressure Measurement
- OTHER Clinical Management
Study Locations (20)
Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC - Burlington
- Aurora Saint Luke's South Shore - Cudahy
- Aurora Health Care Germantown Health Center - Germantown
- Aurora Cancer Care-Grafton - Grafton
- Aurora BayCare Medical Center - Green Bay
- Aurora Cancer Care-Kenosha South - Kenosha
- Aurora Bay Area Medical Group-Marinette - Marinette
- Aurora Cancer Care-Milwaukee - Milwaukee
- Aurora Saint Luke's Medical Center - Milwaukee
- Aurora Sinai Medical Center - Milwaukee
- Vince Lombardi Cancer Clinic - Oshkosh - Oshkosh
- Aurora Cancer Care-Racine - Racine
New York
- Montefiore Medical Center-Einstein Campus - The Bronx
- Montefiore Medical Center-Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Missouri
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04467021
The ClinicalTrials.gov registry entry for NCT04467021 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04467021 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Wisconsin, New York, Missouri.
Frequently Asked Questions
What is clinical trial NCT04467021 about?
NCT04467021 is a clinical study titled "Cancer and Blood Pressure Management, CARISMA Study". This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This stud...
What is the current status of trial NCT04467021?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 61 participants. The study started on 2020-10-29. Estimated completion is 2026-08-31.
What conditions does trial NCT04467021 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Cardiovascular Disorder, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8.
What interventions are being tested in trial NCT04467021?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Best Practice (OTHER), Blood Pressure Measurement (OTHER), Clinical Management (OTHER).
Who is sponsoring clinical trial NCT04467021?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467021 being conducted?
This trial has 20 study locations across Missouri, New York, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
-
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
RECRUITING · NA
-
Transforming Hemodialysis-Related Vascular Access Education
RECRUITING · NA
-
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.